CSPC Pharmaceutical Group's revenue in 2025 is expected to decrease by 10% to 26 billion yuan, with Chairman Cai Dongchen at the age of 71.

Sino Biopharm Liu Zhiying On March 25, CSPC Pharmaceutical Group (01093) announced its full-year results for the year ending December 31, 2025.

In 2025, CSPC Pharmaceutical Group’s revenue was HKD 26.006 billion, a decrease of 10.4% year-on-year, mainly due to the inclusion of Domesol® and Jinyouli® in centralized procurement; gross profit margin slightly declined by 4.4 percentage points to 65.6%; profit attributable to shareholders was HKD 3.882 billion, down 10.3% year-on-year; basic earnings per share attributable to shareholders was RMB 3.534 billion, a decrease of 24.5%.

By business segment, in 2025, the proprietary Chinese medicine business recorded revenue of HKD 20.584 billion (including licensing income of HKD 1.789 billion), a 13.3% decrease from last year; the raw material products business achieved sales of HKD 3.657 billion, up 2.1% year-on-year; functional foods and other businesses had sales of HKD 1.765 billion, an increase of 4.5%, mainly due to steady growth in sales of Guoweikang during the year.

The board recommends a final dividend of HKD 0.15 per share for 2025, combined with an interim dividend of HKD 0.14 per share, totaling HKD 0.29 per share for the full year, an 11.5% increase compared to 2024.

CSPC Chairman Cai Dongchen stated that R&D innovation is the core competitiveness of pharmaceutical companies and the key to solving the “bottleneck” problems and promoting high-quality industry development. In 2025, against the backdrop of continued industry innovation policies, the group continued to increase R&D investment, relying on eight major innovation R&D platforms, and adhered to a demand-driven approach to advance the development and clinical trials of innovative drugs in an orderly manner. In 2025, the group obtained 14 manufacturing approvals and 73 clinical trial approvals, with 5 breakthrough therapies recognized, several of which hold global patents and are highly valuable market-leading products.

According to information, Cai Dongchen, born in 1955, is the Chairman of CSPC Pharmaceutical Group, serving as an executive director since April 1997. Cai Dongchen is also the chairman of the Nomination Committee and a director of several subsidiaries of the company. He holds a master’s degree in Business Administration from Nankai University and has accumulated extensive technical and management experience in the pharmaceutical industry. Cai Dongchen is considered a major shareholder under the Securities and Futures Ordinance Part XV. He is also a director of Liancheng Holdings Limited and Dingda Group Limited.

Related company: CSPC Pharmaceutical Group HK01093